Can an mRNA vaccine stop a rare ebola strain?
NCT ID NCT07737717
First seen Jul 30, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This early-stage trial is testing an experimental mRNA vaccine called mRNA-1469 to see if it is safe and can trigger an immune response against Ebola-Bundibugyo virus disease. Healthy adults aged 18 to 65 will receive either the vaccine or a placebo. The study focuses on safety and the body's antibody production.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental mRNA vaccine called mRNA-1469
- What this could lead to
- If successful, this could lead to a new vaccine against a rare but deadly strain of Ebola virus.
- What could go wrong
- This is an early phase 1 trial with only 84 participants, so safety and immune response are still being tested. The vaccine may not produce strong enough protection or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA-BUNDIBUGYO VIRUS DISEASE (EBOLA-BDBV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Canadian Center for Vaccinology
NOT_YET_RECRUITINGHalifax, Nova Scotia, B3K6R8, Canada
-
Centricity Research Toronto LMC Multispecialty
NOT_YET_RECRUITINGToronto, Ontario, M4G 3E8, Canada
-
Colchester Research Group
RECRUITINGTruro, Nova Scotia, B2N 1L2, Canada